Follicular Lymphoma

• FDA approval · 2018-02-06
  FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)

  The FDA approved a supplemental application for ZYDELIG (idelalisib) filed by Gilead Sciences, Inc.

• FDA approval · 2018-01-26
  FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)

  FDA approved a supplemental application for ZYDELIG (idelalisib) by Gilead Sciences, Inc.

• FDA approval · 2017-06-22
  FDA Approved: RITUXAN HYCELA — Original Application (Genentech, Inc.)

  FDA approved RITUXAN HYCELA (rituximab and hyaluronidase) under an Original Application by Genentech. The subcutaneous formulation provides …

• FDA approval · 2016-09-21
  FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)

  The FDA approved a supplemental application for ZYDELIG (idelalisib) filed by Gilead Sciences, Inc.

• FDA approval · 2016-06-23
  FDA Approved: BENDEKA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

  FDA approved a supplemental application for Bendeka (bendamustine hydrochloride) submitted by Teva Pharmaceuticals USA, Inc., indicating reg…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2015-11-05
  FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)

  FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) submitted by Cephalon, LLC.

• FDA approval · 2015-07-08
  FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)

  FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) submitted by Cephalon, LLC.

• FDA approval · 2014-07-23
  FDA Approved: ZYDELIG — Original Application (Gilead Sciences, Inc.)

  FDA approved ZYDELIG (idelalisib) from Gilead Sciences as a new molecular therapy for adults with relapsed or refractory follicular lymphoma…

• FDA approval · 2013-08-30
  FDA Approved: ZEVALIN — Supplemental Application (Acrotech Biopharma Inc)

  The FDA approved a supplemental application for ZEVALIN (ibritumomab tiuxetan) submitted by Acrotech Biopharma Inc.

• FDA approval · 2011-12-21
  FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)

  The FDA approves a supplemental application for Revlimid (lenalidomide) submitted by Celgene Corporation, updating regulatory status for the…

• FDA approval · 2011-11-18
  FDA Approved: ZEVALIN — Supplemental Application (Acrotech Biopharma Inc)

  FDA approved a supplemental application for ZEVALIN (ibritumomab tiuxetan) submitted by Acrotech Biopharma Inc.

• FDA approval · 2010-10-12
  FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)

  FDA approved a supplemental application for REVLIMID (lenalidomide) submitted by Celgene Corporation.

• FDA approval · 2010-02-26
  FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)

  The FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) from Cephalon, LLC, enabling revisions to its labeling …

• FDA approval · 2009-10-16
  FDA Approved: RITUXAN — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for Rituxan (rituximab) from Genentech.

• FDA approval · 2009-09-03
  FDA Approved: ZEVALIN — Supplemental Application (Acrotech Biopharma Inc)

  The FDA approved a supplemental application for ZEVALIN (ibritumomab tiuxetan) submitted by Acrotech Biopharma Inc. This action updates ZEVA…

• FDA approval · 2008-03-25
  FDA Approved: ZEVALIN — Supplemental Application (Acrotech Biopharma Inc)

  FDA has approved a supplemental application for Zevalin (ibritumomab tiuxetan) filed by Acrotech Biopharma Inc.